AtriCure, Inc. Files Registration Statement for Initial Public Offering.

WEST CHESTER, Ohio -- AtriCure, Inc. announced today that it has filed a registration statement relating to the proposed initial public offering of its common stock with the U.S. Securities and Exchange Commission. UBS Investment Bank and Piper Jaffray & Co. are acting as joint book-running managers of the offering, and Thomas Weisel Partners LLC and A.G. Edwards are acting as co-managers of the offering.

AtriCure, Inc. is a medical device company focused on developing, manufacturing and selling innovative surgical devices designed to safely, rapidly and reliably create precise lesions, or scars, in soft tissues. Leading cardiothoracic surgeons have adopted the AtriCure bipolar ablation system as a standard treatment alternative to create lesions in cardiac, or heart, tissue to block the abnormal electrical impulses that cause atrial fibrillation, or AF, a rapid, irregular quivering of the upper chambers of the heart.

The offering is made only by means of a prospectus. When available, copies of the preliminary prospectus can be obtained from UBS Investment Bank, Attention: Prospectus Dept., 299 Park Avenue, New York, NY 10171, or from Piper Jaffray & Co., 800 Nicollet Mall, Suite 800, Attention: Equity Capital Markets, Minneapolis, MN 55402.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission, but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time that the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of any offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.